Cambridge University Oncology Society

Many thanks to the BMA for sponsoring our upcoming conference! @TheBMA BMA membership is free to first year medical students.

Many thanks to MDU for sponsoring our upcoming conference! themdu.com/join-mdu/medic… @the_mdu (Twitter) @themdu_ (Instagram)

Last day (21 Jan) to register for the Cambridge University Oncology Society Conference (Saturday, 27 January). forms.gle/eNeor1cN5PTPkL…

⭐️CU OncSoc Conference (Saturday, 27 January)⭐️ We are very excited for our diverse range of interactive workshops. Register before Sunday, 21 January: forms.gle/eNeor1cN5PTPkL… @mary_denholm @adnkingdon @J_Kucharczak @hennomartin @ml4cancer

⭐️CU OncSoc Conference (Saturday, 27 January)⭐️ We are very excited for our 3 keynote speakers. Register before Sunday, 21 Jan: forms.gle/eNeor1cN5PTPkL… Prof Paul Workman @ICR_London @Chemical_probes Prof Grant Stewart @grantissimus Prof Axel Behrens @imperialcollege @CR_UK

Dr Henno Martin (@hennomartin) is PhD student in Nitzan Rosenfeld's (@CRUK_CI) and a clinical oncology trainee at Addenbrooke's Hospital.

⭐️CuOncsoc Conference - (27th January 2024) - WORKSHOP ANNOUNCEMENT 5⭐️ REGISTRATION: forms.gle/eNeor1cN5PTPkL…

Dr Raj Jena (@ml4cancer) is a group leader in machine learning and radiomics in the Department of Oncology and an honorary consultant in neuro-oncology at Addenbrooke's Hospital. He leads the AI/ML workstream of the £8.2 million CRUK funded RadNet research programme

⭐️CuOncsoc Conference - (27th January 2024) - WORKSHOP ANNOUNCEMENT 6⭐️ Remember to register for the CuOncSoc 2024 conference using the link below or in our bio! REGISTRATION: forms.gle/eNeor1cN5PTPkL…

Last to submit an abstract. Open to students outside Cambridge too. All shortlisted poster and oral presenters get to attend the conference for free! Submit abstract here: forms.gle/prz8DQbfhjEbto…

2 more days to submit an abstract. Open to students outside Cambridge too. All shortlisted poster and oral presenters get to attend the conference for free! Submit abstract here: forms.gle/prz8DQbfhjEbto…

CONFERENCE POSTER & ORAL PRESENTATIONS DEADLINE EXTENDED- if you would like to present your Oncology-related research in our conference, please submit your abstract using the google form forms.gle/1aEEGbwsk2ScNd… NEW Deadline for submission is 15th January 2024!

CONFERENCE POSTER & ORAL PRESENTATIONS DEADLINE EXTENDED- if you would like to present your Oncology-related research in our conference, please submit your abstract using the google form forms.gle/1aEEGbwsk2ScNd… Deadline for submission is in 2 days (15th January 2024!)

⭐️CuOncsoc Conference - (27th January 2024) - WORKSHOP ANNOUNCEMENT 4⭐️ REGISTRATION: forms.gle/eNeor1cN5PTPkL… POSTER AND ORAL PRESENTATIONS : forms.gle/prz8DQbfhjEbto…

The CRUK Convergence Science Centre is a partnership between @imperialcollege , @ICR_London , and @CR_UK, with a mission to bring together engineering, physical sciences, life sciences and medicine to develop innovative ways to address challenges in cancer research.

⭐️ CU OncSoc Conference - (27 Jan 2024) - Keynote Talk 3⭐️ We are delighted to introduce Prof Axel Behrens, Scientific Director of the @CR_UK Convergence Science Centre, as our final keynote speaker. REGISTER: forms.gle/eNeor1cN5PTPkL… SUBMIT ABSTRACT: forms.gle/prz8DQbfhjEbto…

As a urological surgeon, Grant has a specific interest in optimising the management of patients with initially localised renal cancer, by the development of early detection and optimal peri-surgical management.

Grant Stewart is the Professor of Surgical Oncology and Honorary Consultant Urological Surgeon at Addenbrooke's Hospital. He is also the Director of the Academic Clinical Fellow Programme in Cambridge.

⭐️ CU OncSoc Conference - (27 Jan 2024) - Keynote Talk 2 ⭐️ We are delighted to introduce urological surgeon Prof Grant Stewart (@grantissimus) as our next keynote speaker for the conference. REGISTER: forms.gle/eNeor1cN5PTPkL… SUBMIT ABSTRACT: forms.gle/prz8DQbfhjEbto…

@ICR_London @Chemical_probes In addition to his distinguished career in academia, Prof Workman has also spent many years in industry at AstraZeneca and is the scientific founder of multiple biotech companies.

@ICR_London @Chemical_probes Prof Workman is renowned for his research in molecularly targeted cancer drugs. Of note, Paul has been instrumental in the discovery of two approved drugs: the EGFR inhibitor gefitinib for lung cancer and the AKT inhibitor capivasertib for breast cancer.

⭐️ CU OncSoc Conference - (27 Jan 2024) - Keynote Talk 1 ⭐️ We are excited to introduce Prof Paul Workman, former Chief Executive of @ICR_London and current Director of @Chemical_probes REGISTER: forms.gle/eNeor1cN5PTPkL… SUBMIT ABSTRACT: forms.gle/prz8DQbfhjEbto…